肺癌中埃罗替尼—结果的分子和临床预测。
Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome.
此外，埃罗替尼是一种口服药，因此，在给药方面较静脉注射化疗药物更为方便。
In addition, erlotinib is an oral agent, so it is more convenient to administer than IV chemotherapy.
例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。
For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.
在术前，患者每两周一次静脉接受贝伐单抗，持续四周；同时，每天口服埃罗替尼，持续八周。
The patients received bevacizumab intravenously once every two weeks for four weeks and took erlotinib orally every day for eight weeks before they had surgery.
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
对埃罗替尼治疗的反应率，仅在肿瘤组织中存在变异的患者和那些肿瘤和血浆中均存在变异的患者是相似的(67%)。
The response rate to erlotinib therapy was similar in patients with tumor-only mutations and in those with tumor and serum mutations (67%).
对埃罗替尼治疗的反应率，仅在肿瘤组织中存在变异的患者和那些肿瘤和血浆中均存在变异的患者是相似的(67%)。
The response rate to erlotinib therapy was similar in patients with tumor-only mutations and in those with tumor and serum mutations (67%).
应用推荐